Abstract: The invention relates to AAV gene therapy vectors containing novel deoxyribonuclease (DNase) transgene for delivery and expression of an enzyme which has a deoxyribonuclease (DNase) activity for enhanced clearance of cell-free DNA (cfDNA) accumulated intravasculary and/or extravasculary for treatment of various diseases and conditions, including cancer and neurodegeneration.

Abstract: The invention provides methods for induction of pregnancy in a couple in need thereof wherein the male subject in said couple has been diagnosed as sub-fertile, said method comprising administering systemically to said male subject a pharmaceutical composition comprising a human DNase.

Abstract: A composition comprising a population of polysaccharide-blinatumomab conjugates, wherein the polysaccharide is covalently linked to the blinatumomab. A method of increasing the efficacy of a therapeutic agent in the treatment of B-cell precursor acute lymphoblastic leukemia (ALL), wherein the therapeutic agent is a PSA-drug conjugate, wherein the conjugate comprises PSA covalently linked to blinatumomab, and wherein the PSA of the conjugate binds to DNA and histones of NET extracellular fibrils.

Abstract: The present invention demonstrates that erythropoietin (EPO)-receptor (EPOR) is a malignant myeloma biomarker of sensitivity to EPO treatment and, itself a target for myeloma treatment. A low EPOR level in a myeloma cells of the subject indicates non-response to EPO treatment. Patients having high EPOR level in myeloma cells can be effectively treated with EPO, in particular an EPO derivatized with polysialic acid.

Abstract: The present invention provides conjugates of deoxyribonuclease enzymes with water soluble polymers such as PSA having improved pharmacokinetic attributes. These modifications provide unexpectedly high levels of DNA hydrolytic activity in blood and other bodily tissues over the time due to markedly increased distribution phase and reduced clearance of DNase conjugates after delivery to blood circulation relative to the unconjugated compounds, while half-life and residence time of conjugates remains almost unchanged compared to the unconjugated DNase compounds. The compositions of the invention are used for parenteral treatment of diseases related to NET formation and the presence of extracellular DNA.

Abstract: The present invention demonstrates that erythropoietin (EPO)-receptor (EPOR) is a malignant myeloma biomarker of sensitivity to EPO treatment and, itself a target for myeloma treatment. A low EPOR level in a myeloma cells of the subject indicates non-response to EPO treatment. Patients having high EPOR level in myeloma cells can be effectively treated with EPO, in particular an EPO derivatized with polysialic acid.

Abstract: The invention provides a method for treatment of primary progesterone receptor-negative (PR?) endometrial cancer comprising administering (i) cridanimod or a salt or an ester thereof and (ii) a progesterone receptor (PR) agonist. The invention further provides a method for treatment of a primary estrogen receptor-negative (ER?) breast cancer, comprising administering (i) cridanimod or a salt or an ester thereof and (ii) a selective estrogen receptor modulator (SERM) or a selective estrogen receptor down-regulator (SERD). Also provided are compositions related to the above methods.

Abstract: The present invention provides conjugates of deoxyribonuclease enzymes with water soluble polymers such as PSA having improved pharmacokinetic attributes. These modifications provide unexpectedly high levels of DNA hydrolytic activity in blood and other bodily tissues over the time due to markedly increased distribution phase and reduced clearance of DNase conjugates after delivery to blood circulation relative to the unconjugated compounds, while half-life and residence time of conjugates remains almost unchanged compared to the unconjugated DNase compounds. The compositions of the invention are used for parenteral treatment of diseases related to NET formation and the presence of extracellular DNA.

Abstract: The present invention provides a method of intranasal delivery of a pharmaceutical composition, comprising a polysaccharide derivative of insulin protein and a one or more pharmaceutically acceptable excipients, to a subject, wherein the insulin protein is delivered to the brain of the subject through the nasal mucosa.

Abstract: The invention provides a method for treatment of primary progesterone receptor-negative (PR?) endometrial cancer comprising administering (i) cridanimod or a salt or an ester thereof and (ii) a progesterone receptor (PR) agonist. The invention further provides a method for treatment of a primary estrogen receptor-negative (ER?) breast cancer, comprising administering (i) cridanimod or a salt or an ester thereof and (ii) a selective estrogen receptor modulator (SERM) or a selective estrogen receptor down-regulator (SERD). Also provided are compositions related to the above methods.

Abstract: The invention provides a method for treatment of primary progesterone receptor-negative (PR?) endometrial cancer comprising administering (i) cridanimod or a salt or an ester thereof and (ii) a progesterone receptor (PR) agonist. The invention further provides a method for treatment of a primary estrogen receptor-negative (ER?) breast cancer, comprising administering (i) cridanimod or a salt or an ester thereof and (ii) a selective estrogen receptor modulator (SERM) or a selective estrogen receptor down-regulator (SERD). Also provided are compositions related to the above methods.

Abstract: The present invention provides a method of intranasal delivery of a pharmaceutical composition, comprising a polysaccharide derivative of insulin protein and a one or more pharmaceutically acceptable excipients, to a subject, wherein the insulin protein is delivered to the brain of the subject through the nasal mucosa.

Abstract: The invention relates to medicine and veterinary science and discloses a novel method for treating oncological, virulent and somatic diseases whose main target for therapeutic action is embodied in the form of DNA which freely circulates in blood plasma (and other liquid media) and originates from tumoral and mutant cells or cells infected by bacteria, fungi or protozoan and from different microorganisms which reside in the organism thereof. Said invention also relates to novel pharmaceutical compositions and to the use thereof for treating oncological diseases and infectious states provoked by bacteria, fungi and protozoa and non-infectious somatic diseases and states produced by accumulation of somatic mutations in cells of organism. Medicinal and immunological compositions, sorption and physico-chemical engineering and the method for using them in order to treat malignant tumors and other diseases are also disclosed.

Abstract: The invention relates to medicine and veterinary science and can be used for treating diseases associated with changes of the qualitative and/quantitative composition of blood extracellular DNA, namely generalised infection diseases provoked by bacteria, diseases provoked by fungi and protozoa, atherosclerosis, pancreatic diabetes, allergic diseases associated with delayed response hypersensitivity and diseases due to somatic cell gene mutations. The inventive method for treating diseases associated with modifications of the qualitative and/or quantitative composition of blood extracellular DNA, namely generalised infection diseases provoked by bacteria, diseases provoked by fungi and protozoa, atherosclerosis, pancreatic diabetes, allergic diseases associated with delayed response hypersensitivity and diseases due to somatic cell gene mutations consists in injecting an agent destroying blood extracellular DNA.

Abstract: The invention relates to medicine and veterinary science and can be used for treating mainly solid tumors. The inventive method for treating oncological diseases consisting in injecting a blood extracellular DNA destroying agent into a systemic blood circulation. Said blood extracellular DNA destroying agent can be embodied in the form of a DNAse enzyme, in particular a bovine pancreatic DNAse which is parenterally injected in doses ranging from of 50 000 Kunz units to 250 000 000 Kunz units a day every day during 5-360 days or in the form of a recombinant human DNAse. In addition, a blood extracellular DNA binding agent embodied in the form of anti-DNA antibodies can be injected into a systemic blood circulation. In addition a modified agent which modifies the chemical composition and/or conformation and/or polymery and/or an association with proteins and/or lipids and/or ribonucleic acids of the blood extracellular DNA. Said modifying agent can be embodied in the form of a enzyme-ribonuclease.